Sickle cell anemia (SCA) is a hemoglobinopathy caused by a point mutation in the β-globin gene characterized by vaso-occlusive events and a chronic inflammatory state. Studies have demonstrated new treatment options in SCA in order to potentiate the action of Hydroxyurea (HU) and thereby promote decreased dosage without compromising fetal hemoglobin concentration, as well as the use of substances that may act i...
Objective: This study aimed to evaluate the influence of fetal hemoglobin (Hb F) on hemolysis biomarkers in sickle cell anemia patients. Methods: Fifty adult sickle cell anemia patients were included in the study. All patients were taking hydroxyurea for at least six months and were followed at the outpatient clinic of a hospital in Fortaleza, Ceará, Brazil. The control group consisted of 20 hemoglobin AA indiv...